HighTower Advisors
SABS icon

HighTower Advisors’s SAB Biotherapeutics SABS Stock Holding History

HighTower Advisors’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,347
Closed -$46K – 3827
2023
Q3 		$46K Hold
7,347
– – ﹤0.01% 3242
2023
Q2 		$61K Hold
7,347
– – ﹤0.01% 3145
2023
Q1 		$32K Sell
7,347
-250
-3% -$1.58K ﹤0.01% 3096
2022
Q4 		$44K Buy
+7,597
New +$69.4K ﹤0.01% 3054
2021
Q2 		– Sell
-1,000
Closed -$98K – 3356
2021
Q1 		$98K Buy
+1,000
New +$100K ﹤0.01% 2766

Other funds holding SABS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors's SABS Position: Q4 2023 in Review

HighTower Advisors sold out of SAB Biotherapeutics (SABS) in Q4 2023, closing a stake of 7,347 shares — an estimated $46K sold.

HighTower Advisors first reported a position in SABS in Q1 2021 and held it in 5 quarters. The position peaked at $98K in Q1 2021. 42 funds tracked by Wall St. Rank hold SABS as of Q4 2023.

  • HighTower Advisors reported no remaining SAB Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • HighTower Advisors sold 7,347 SAB Biotherapeutics shares in Q4 2023, an estimated $46K.
  • HighTower Advisors first reported a position in SAB Biotherapeutics in Q1 2021 and held it in 5 quarters.
  • HighTower Advisors's SAB Biotherapeutics position peaked at $98K in Q1 2021.
  • 42 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2023.

Based on HighTower Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.